These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 26181193)

  • 41. Tubal origin of ovarian cancer - the double-edged sword of haemoglobin.
    Lin SF; Gerry E; Shih IM
    J Pathol; 2017 May; 242(1):3-6. PubMed ID: 28054715
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study.
    Meserve EEK; Mirkovic J; Conner JR; Yang E; Muto MG; Horowitz N; Strickland KC; Howitt BE; Crum CP
    Gynecol Oncol; 2017 Jul; 146(1):69-73. PubMed ID: 28479065
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    Patrono MG; Iniesta MD; Malpica A; Lu KH; Fernandez RO; Salvo G; Ramirez PT
    Gynecol Oncol; 2015 Dec; 139(3):568-72. PubMed ID: 26407480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Methylomic Landscapes of Ovarian Cancer Precursor Lesions.
    Pisanic TR; Wang Y; Sun H; Considine M; Li L; Wang TH; Wang TL; Shih IM
    Clin Cancer Res; 2020 Dec; 26(23):6310-6320. PubMed ID: 32817081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
    Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
    J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.
    Novak M; Lester J; Karst AM; Parkash V; Hirsch MS; Crum CP; Karlan BY; Drapkin R
    Gynecol Oncol; 2015 Oct; 139(1):104-11. PubMed ID: 26206555
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?
    Gao FF; Bhargava R; Yang H; Li Z; Zhao C
    Hum Pathol; 2013 Aug; 44(8):1534-43. PubMed ID: 23465279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase.
    Sehdev AS; Kurman RJ; Kuhn E; Shih IeM
    Mod Pathol; 2010 Jun; 23(6):844-55. PubMed ID: 20228782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ovarian Carcinosarcoma and Concurrent Serous Tubal Intraepithelial Carcinoma With Next-Generation Sequencing Suggesting an Origin From the Fallopian Tube.
    See SHC; Behdad A; Maniar KP; Blanco LZ
    Int J Surg Pathol; 2019 Aug; 27(5):574-579. PubMed ID: 30913944
    [No Abstract]   [Full Text] [Related]  

  • 51. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia.
    Rabban JT; Vohra P; Zaloudek CJ
    Am J Surg Pathol; 2015 Jan; 39(1):35-51. PubMed ID: 25025442
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serous tubal intraepithelial carcinoma localizes to the tubal-peritoneal junction: a pivotal clue to the site of origin of extrauterine high-grade serous carcinoma (ovarian cancer).
    Seidman JD
    Int J Gynecol Pathol; 2015 Mar; 34(2):112-20. PubMed ID: 25675178
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
    Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
    Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status.
    George SH; Milea A; Shaw PA
    Clin Cancer Res; 2012 Nov; 18(22):6199-207. PubMed ID: 22967960
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA damage signaling and apoptosis in preinvasive tubal lesions of ovarian carcinoma.
    Chene G; Ouellet V; Rahimi K; Barres V; Caceres K; Meunier L; Cyr L; De Ladurantaye M; Provencher D; Mes Masson AM
    Int J Gynecol Cancer; 2015 Jun; 25(5):761-9. PubMed ID: 24987917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High grade serous ovarian carcinomas originate in the fallopian tube.
    Labidi-Galy SI; Papp E; Hallberg D; Niknafs N; Adleff V; Noe M; Bhattacharya R; Novak M; Jones S; Phallen J; Hruban CA; Hirsch MS; Lin DI; Schwartz L; Maire CL; Tille JC; Bowden M; Ayhan A; Wood LD; Scharpf RB; Kurman R; Wang TL; Shih IM; Karchin R; Drapkin R; Velculescu VE
    Nat Commun; 2017 Oct; 8(1):1093. PubMed ID: 29061967
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting DNA repair: the genome as a potential biomarker.
    Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
    J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
    Aisagbonhi O; Ghlichloo I; Hong DS; Roma A; Fadare O; Eskander R; Saenz C; Fisch KM; Song W
    Gynecol Oncol; 2024 Aug; 187():241-248. PubMed ID: 38833993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.